Sun Pharmaceutical Industries Limited (($IN:SUNPHARMA)) announced an update on their ongoing clinical study. Sun Pharmaceutical Industries Limited ...
TipRanks on MSN
Sun Pharma’s New Clinical Trial: A Potential Game-Changer for Actinic Keratosis Treatment
Sun Pharmaceutical Industries Limited (($IN:SUNPHARMA)) announced an update on their ongoing clinical study. Sun Pharmaceutical Industries Limited ...
Torqur AG, subsidiary of Swiss Rockets incubator and a clinical-stage company advancing targeted therapies in oncodermatology and oncology, announced the results of the full Phase 2 proof-of-concept ...
Torqur AG Announced Full Phase 2 Results at EADV Congress 2025 BASEL, Switzerland, October 06, 2025--(BUSINESS WIRE)--Torqur AG, subsidiary of Swiss Rockets incubator and a clinical-stage company ...
Background: Differentiating Actinic keratosis (AK) from Seborrheic keratosis (SK) can be challenging for dermatologists due to their visual similarities. This multi-center prospective study aims to ...
IND clearance marks second study accepted for RLS-1496, a first-in-class disease-modifying selective GPX4 modulator targeting pathological senescent cells that drive inflammaging and chronic ...
PARIS--(BUSINESS WIRE)--Almirall, S.A. (ALM) a global biopharmaceutical company dedicated to medical dermatology, is a major contributor to the 2025 European Academy of Dermatology and Venereology ...
WOBURN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...
A 62-year-old man visited his doctor about rough, scaly spots on his chest, arms, and hands. The spots had been present for some months but lately they had become more red and inflamed. The patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback